Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19.
Michael DouganAjay NirulaMasoud AzizadBharat MocherlaRobert L GottliebPeter ChenCorey HebertRussell PerryJoseph BosciaBarry HellerJason MorrisChad CrystalAwawu IgbinadolorGregory HuhnJose CardonaImad ShawaPrincy KumarAndrew C AdamsJacob Van NaardenKenneth L CusterMichael DuranteGerard OakleyAndrew E SchadeTimothy R HolzerPhilip J EbertRichard E HiggsNicole L KallewaardJanelle SaboDipak R PatelMatan C DaboraPaul KlekotkaLei ShenDaniel M Skovronskynull nullPublished in: The New England journal of medicine (2021)
Among high-risk ambulatory patients, bamlanivimab plus etesevimab led to a lower incidence of Covid-19-related hospitalization and death than did placebo and accelerated the decline in the SARS-CoV-2 viral load. (Funded by Eli Lilly; BLAZE-1 ClinicalTrials.gov number, NCT04427501.).